ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Pulse Biosciences to Present at the Stifel 2021 Virtual Healthcare Conference

November 4, 2021 GMT

HAYWARD, Calif.--(BUSINESS WIRE)--Nov 4, 2021--

Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company introducing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced that members of management will present at the Stifel 2021 Virtual Healthcare Conference on Wednesday, November 17, 2021 at 1:40pm PT / 4:40pm ET.

Interested parties may access the on-demand webcast at the same time on the “Investors” section of the Company’s website at www.pulsebiosciences.com.

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company’s proprietary Nano-Pulse Stimulation™ (NPS™) technology delivers nano-second pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue. The CellFX® System is the first commercial product to harness the distinctive advantages of NPS technology to treat a variety of applications for which an optimal solution remains unfulfilled. The initial commercial use of the CellFX System is to address a range of dermatologic conditions that share high demand among patients and practitioners for improved dermatologic outcomes. Designed as a multi-application platform, the CellFX System offers customer value with a utilization-based revenue model. Visit pulsebiosciences.com to learn more.

ADVERTISEMENT

To stay informed about the CellFX System, please visit CellFX.com and sign-up for updates.

Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

ADVERTISEMENT

View source version on businesswire.com:https://www.businesswire.com/news/home/20211104006183/en/

CONTACT: Investors:

Pulse Biosciences

Sandra Gardiner, EVP and CFO

510.241.1077

IR@pulsebiosciences.com

or

Gilmartin Group

Philip Trip Taylor

415.937.5406

philip@gilmartinir.comMedia:

Tosk Communications

Nadine D. Tosk

504.453.8344

nadinepr@gmail.comor

press@pulsebiosciences.com

KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH MEDICAL DEVICES

SOURCE: Pulse Biosciences, Inc.

Copyright Business Wire 2021.

PUB: 11/04/2021 04:05 PM/DISC: 11/04/2021 04:07 PM

http://www.businesswire.com/news/home/20211104006183/en